Benefits and ROI of eCOA Data Collection in Clinical Trials

Patient-reported outcome (PRO) and electronic PRO (ePRO) measures are standard tools for directly eliciting the patient experience for clinical outcome assessments (COA). Ever since regulators approved quality of life (QoL) data sufficient to prove efficacy, clinical trials have been leveraging COAs and electronic COAs (eCOA) for submissions.

In this webinar, the presenters will examine three key benefits of electronic clinical outcome assessments: reduced data variance, increased patient compliance and reduced site monitoring costs. Hear lessons learned and experience gained from real-world trials collecting eCOA data.

Industry trends, research and best practices in eCOA will be discussed, including:

• Regulatory mandates & recommendations;
• Patient eData adoption and trends;
• eCOA case studies of increased compliance & data quality;
• Comparisons of monitoring costs for eCOA vs. paper; and

Speakers

Elisabeth Kurkimilis, Senior Manager of Clinical Operations, Celgene Corporation

Elisabeth is a senior manager of clinical operations at Celgene Corporation. She is currently responsible for a Global Phase III Program in the inflammation and immunology department at Celgene. The program spans over 20 countries and is comprised of four trials enrolling 2000 subjects. Elisabeth has over 25 years of experience in the Pharmaceutical industry starting her career as a study coordinator, then as a CRA and currently as a senior study manager. Therapeutic areas that Elisabeth has worked in include: anti-infectives, chronic and acute pain management, asthma, oncology, and inflammation and immunology. Elisabeth is located in Eagleville, PA and has her BS from the University of South Florida.

Message Presenter

Valdo Arnera, MD, General Manager Europe, PHT Corporation

Valdo is a physician, scientist and entrepreneur who has advanced Pharmaceutical research for over 20 years. Since founding PHT Europe in 2001, he has opened multiple geographies for PHT. Valdo received the SCRIP Journal Lifetime Achievement award for his work in advancing clinical research, and has been named to the PharmaVOICE 100 list of the most influential people in the life sciences industries. Previously he founded the first European Central Clinical Laboratory, which became the Covance Central Laboratory, and practiced medicine. Valdo has published articles in top industry publications, and speaks frequently at events which foster clinical research advances. He received his French State Doctor’s Degree in Medicine from the University of Clermont-Ferrand I.

Message Presenter